Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 40% Improvement Relative Risk c19hcq.org Cordtz et al. HCQ for COVID-19 PrEP Favors HCQ Favors control
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
Cordtz et al., Journal of Clinical Medicine, doi:10.3390/jcm10173842
Cordtz et al., Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study.., Journal of Clinical Medicine, doi:10.3390/jcm10173842
Aug 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2,533 SLE patients in Denmark showing no significant difference in hospitalization risk for COVID-19 cases with HCQ treatment.
risk of hospitalization, 40.0% lower, HR 0.60, p = 0.39, treatment 1,170, control 1,363, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cordtz et al., 27 Aug 2021, retrospective, population-based cohort, Denmark, peer-reviewed, 8 authors, study period 1 March, 2020 - 2 February, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Clinical Medicine Article Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark René Cordtz 1,2, *,† , Salome Kristensen 1,3,† , Louise Plank Holm Dalgaard 1 , Rasmus Westermann 1 , Kirsten Duch 1,4 , Jesper Lindhardsen 5 , Christian Torp-Pedersen 6,7 and Lene Dreyer 1,2,3 1 2 3 4 5 6   7 * † Department of Rheumatology, Aalborg University Hospital, 9000 Aalborg, Denmark; sakr@rn.dk (S.K.); louise.dalgaard@rn.dk (L.P.H.D.); raw@rn.dk (R.W.); k.duch@rn.dk (K.D.); l.dreyer@rn.dk (L.D.) Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte Hospital, 2900 Hellerup, Denmark Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark Unit of Clinical Biostatistics, Aalborg University Hospital, 9000 Aalborg, Denmark Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, 2100 Copenhagen, Denmark; jesper.lindhardsen@regionh.dk Department of Cardiology, Nordsjællands Hospital, 3400 Hillerod, Denmark; christian.torp-pedersen.01@regionh.dk Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark Correspondence: r.cordtz@rn.dk Shared first authorship/contributed equally. Citation: Cordtz, R.; Kristensen, S.; Dalgaard, L.P.H.; Westermann, R.; Duch, K.; Lindhardsen, J.; Torp-Pedersen, C.; Dreyer, L. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark. J. Clin. Med. 2021, 10, 3842. https://doi.org/10.3390/ jcm10173842 Academic Editors: Christopher Sjöwall and Ioannis Parodis Received: 30 July 2021 Accepted: 23 August 2021 Published: 27 August 2021 Abstract: Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76–10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55–4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19–1.88), and 1.06 (95% CI 0.3–3.72) for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation with COVID-19. Keywords: systemic lupus erythematosus; COVID-19; hydroxychloroquine; glucocorticoids Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). 1...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit